Table 1 Patient characteristics
Patient characteristics | All N = 414 | No irAE N = 316 | irAE N = 98 | p-value |
|---|---|---|---|---|
Median Age (range) | 63 (17–97) | 64 (17–97) | 63 (20–91) |  |
  < 65 years-old | 226 (54.6) | 170 (53.8) | 56 (57.1) | 0.561 |
  ≥ 65 years-old | 188 (45.4) | 146 (46.2) | 42 (82.9) |  |
Gender | Â | Â | Â | 0.627 |
 Male | 287 (69.3) | 221 (69.9) | 66 (67.4) |  |
 Female | 127 (30.7) | 95 (30.1) | 32 (32.6) |  |
Smoking status | Â | Â | Â | 0.989 |
 Never | 142 (34.3) | 108 (34.2) | 34 (34.7) |  |
 Active or ex-smoker | 142 (34.3) | 109 (34.5) | 33 (33.7) |  |
 Unknown | 130 (31.4) | 99 (31.3) | 31 (31.7) |  |
ECOG status | Â | Â | Â | 0.431 |
 0–1 | 394 (95.2) | 299 (94.6) | 95 (96.9) |  |
  ≥ 2 | 20 (4.8) | 17 (5.4) | 3 (3.1) |  |
Comorbidity of Interest | ||||
 Hypothyroidism | 15 (3.6) | 6 (1.9) | 9 (9.2) | 0.001 |
 Hyperthyroidism | 5 (1.2) | 4 (1.3) | 1 (1.0) | 1.000 |
 DM | 68 (16.4) | 53 (16.8) | 15 (15.3) | 0.732 |
 Chronic HBV | 28 (6.8) | 24 (7.6) | 4 (4.1) | 0.355 |
 Chronic HCV | 9 (2.2) | 8 (2.5) | 1 (1.0) | 0.692 |
Primary Tumor types | Â | Â | Â | 0.031 |
 Lung cancer | 193 (46.6) | 156 (49.4) | 37 (37.8) |  |
 HCCa | 42 (10.1) | 30 (9.5) | 12 (12.2) |  |
 Bladder cancer/TCCa | 40 (9.7) | 30 (9.5) | 10 (10.2) |  |
 Melanoma | 33 (8.0) | 21 (6.7) | 12 (12.2) |  |
 HNSCCa | 23 (5.6) | 19 (6.0) | 4 (4.1) |  |
 RCCa | 20 (4.8) | 16 (5.1) | 4 (4.1) |  |
 Nasopharyngeal carcinoma | 19 (4.6) | 12 (3.8) | 7 (7.2) |  |
 Esophageal cancer | 8 (1.9) | 6 (1.9) | 2 (2.0) |  |
 Colorectal cancer | 7 (1.7) | 4 (1.3) | 3 (3.1) |  |
 Breast cancer | 6 (1.4) | 6 (1.9) | 0 |  |
 Pancreatic cancer | 4 (1.0) | 1 (0.3) | 3(3.1) |  |
 Stomach/EGJa cancer | 3 (0.7) | 1 (0.3) | 2 (2.0) |  |
 Cholangiocarcinoma | 2 (0.5) | 1 (0.3) | 1 (1.0) |  |
 Others | 14 (3.4) | 13 (3.0) | 1 (1.0) |  |
Histology | Â | Â | Â | 0.122 |
 Adenocarcinoma | 212 (51.2) | 163 (51.6) | 49 (50.0) |  |
 Squamous Cell | 79 (19.1) | 58 (18.3) | 21 (21.4) |  |
 Transitional cell carcinoma | 41 (9.9) | 31 (9.8) | 10 (10.2) |  |
 Melanoma | 36 (8.7) | 23 (7.3) | 13 (13.3) |  |
 Clear cell | 15 (3.6) | 12 (3.8) | 3 (3.1) |  |
 Others | 31 (7.5) | 29 (9.2) | 2 (2.0) |  |
PD-L1 status | Â | Â | Â | 0.065 |
 Negative | 39 (9.4) | 29 (9.2) | 10 (10.2) |  |
 Positive | 70 (16.9) | 61 (19.3) | 9 (9.2) |  |
 Unknown | 305 (73.7) | 226 (71.5) | 79 (80.6) |  |
Previous Treatment | ||||
 Chemotherapy | 250 (60.4) | 198 (62.7) | 52 (53.1) | 0.090 |
 Radiotherapy | 167 (40.3) | 128 (40.5) | 39 (39.8) | 0.900 |
 Site of previous Radiotherapy | ||||
  Lung | 32 (7.7) | 24 (7.6) | 8 (8.2) | 0.854 |
 Mediastinum | 15 (3.6) | 10 (3.2) | 5 (5.1) | 0.370 |
 Neck/thyroid | 24 (5.8) | 17 (5.4) | 7 (7.1) | 0.514 |